ArticleACS omega2025
Identification of Neurotrophic Factor Related Biomarkers and Mechanistic Insights into Neuropathic Pain via Integrated Bioinformatics Analysis.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophic factors are closely associated with the development of neuropathic pain (NPP), yet their underlying mechanisms remain unclear. This study aims to identify key biomarkers and explore their potential mechanisms using integrated bioinformatics approaches. The data sets of NPP were retrieved from public databases. Single-cell RNA sequencing analysis of mouse dorsal root ganglion (DRG) was executed to identify and annotate cell clusters. Differential expression analyses, Friend analysis, and expression validation were executed to screen biomarkers. Gene-gene interaction (GGI) network construction and enrichment analyses were used to explore the relevant functions of the biomarkers. Immune microenvironment differences between case and control were assessed by single sample gene set enrichment analysis (ssGSEA) and CIBERSORT algorithm. Mendelian randomization (MR) analysis explored potential causal relationships between biomarkers and NPP. Cellular communication and pseudotime analyses further elucidated intercellular interactions and differentiation trajectories in key cell populations. Single-cell analysis of mouse DRG identified 10 cell types. There was a significant difference in satellite glial cells (SGCs) between the two groups, and their proportion in the NPP case group was significantly reduced. Differential expression analyses revealed 792 highly expressed genes of SGCs, 556 differentially expressed genes related to neurotrophic factor-related gene (NFRG) scores, and 701 differentially expressed genes in bulk RNA-seq data set. Intersection analysis identified five biomarkers: Myo10, Rhoq, Sema6a, Spata13, and Id4. GSEA analysis revealed their involvement in key pathways, including ribosomes, p53 signaling, oxidative phosphorylation, and neuroactive ligand-receptor interaction. Immune microenvironment analysis highlighted correlations between Myo10 and M2 macrophages. MR analysis demonstrated a potential causal link between Myo10 and drug-induced neuropathy, as well as Sema6a with reduced risk of sciatica. Cell communication and pseudotime analyses indicated enhanced SGC interactions and increased biomarker expression during late differentiation stages. This study identified five neurotrophic factor-related biomarkers (Myo10, Rhoq, Sema6a, Spata13, and Id4), providing novel targets for the diagnosis and treatment of NPP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.